[go: up one dir, main page]

AR125450A1 - Anticuerpos anti-adgre2 y usos de los mismos - Google Patents

Anticuerpos anti-adgre2 y usos de los mismos

Info

Publication number
AR125450A1
AR125450A1 ARP220101068A ARP220101068A AR125450A1 AR 125450 A1 AR125450 A1 AR 125450A1 AR P220101068 A ARP220101068 A AR P220101068A AR P220101068 A ARP220101068 A AR P220101068A AR 125450 A1 AR125450 A1 AR 125450A1
Authority
AR
Argentina
Prior art keywords
antibodies
adgre2
fragments
fusion proteins
cancers
Prior art date
Application number
ARP220101068A
Other languages
English (en)
Inventor
Antara Banerjee
Xingyue He
Shawn Jennings
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR125450A1 publication Critical patent/AR125450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos, fragmentos de los mismos y proteínas de fusión que se unen específicamente a ADGRE2, así como métodos preparación y uso de tales anticuerpos. Estos anticuerpos, proteínas de fusión y fragmentos de los mismos son de utilidad para el tratamiento y el diagnóstico de diversas enfermedades autoinmunes y cánceres, incluyendo, por ejemplo, leucemia mieloide aguda.
ARP220101068A 2021-04-26 2022-04-25 Anticuerpos anti-adgre2 y usos de los mismos AR125450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179756P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
AR125450A1 true AR125450A1 (es) 2023-07-19

Family

ID=81648880

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101068A AR125450A1 (es) 2021-04-26 2022-04-25 Anticuerpos anti-adgre2 y usos de los mismos

Country Status (17)

Country Link
US (1) US12540178B2 (es)
EP (1) EP4330283A1 (es)
JP (1) JP2024518776A (es)
KR (1) KR20240004287A (es)
CN (1) CN117580860A (es)
AR (1) AR125450A1 (es)
AU (1) AU2022266583A1 (es)
BR (1) BR112023020371A2 (es)
CA (1) CA3214355A1 (es)
CL (1) CL2023003174A1 (es)
CO (1) CO2023013195A2 (es)
EC (1) ECSP23088752A (es)
IL (1) IL307940A (es)
MX (1) MX2023011712A (es)
PE (1) PE20242205A1 (es)
TW (1) TW202305003A (es)
WO (1) WO2022232035A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518776A (ja) 2021-04-26 2024-05-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗ａｄｇｒｅ２抗体及びその使用
IL306141A (en) 2021-04-26 2023-11-01 Memorial Sloan Kettering Cancer Center Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
US20240180968A1 (en) * 2022-10-25 2024-06-06 Takeda Pharmaceutical Company Limited Adgre2 chimeric receptor nk cell compositions and methods of use
WO2024238565A1 (en) * 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025243243A1 (en) * 2024-05-24 2025-11-27 Janssen Biotech, Inc. Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0732397A3 (en) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69128893T2 (de) 1990-10-31 1998-09-10 Brigham & Womens Hospital Genetische veränderung von endothelzellen
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT970126E (pt) 1997-04-14 2001-10-30 Micromet Ag Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2001271417B2 (en) 2000-08-30 2006-10-05 Johns Hopkins University Devices for intraocular drug delivery
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7556615B2 (en) 2001-09-12 2009-07-07 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US20090110679A1 (en) 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
KR20150002894A (ko) 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
WO2012044831A1 (en) 2010-09-30 2012-04-05 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
JP6296536B2 (ja) * 2010-11-05 2018-03-20 メドベット サイエンス ピーティーワイエルティーディーＭｅｄｖｅｔ Ｓｃｉｅｎｃｅ Ｐｔｙ Ｌｔｄ 内皮前駆細胞のマーカーおよびその使用
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
WO2017087800A1 (en) * 2015-11-19 2017-05-26 Abbvie Stemcentrx Llc Novel anti-emr2 antibodies and methods of use
WO2018027197A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
KR20210005240A (ko) 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
JP2024518776A (ja) 2021-04-26 2024-05-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗ａｄｇｒｅ２抗体及びその使用
IL306141A (en) 2021-04-26 2023-11-01 Memorial Sloan Kettering Cancer Center Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
CN117545774A (zh) 2021-04-26 2024-02-09 米伦纽姆医药公司 抗clec12a抗体及其用途
CN114106199B (zh) 2021-11-19 2022-07-12 广州百暨基因科技有限公司 靶向adgre2的嵌合抗原受体及其应用
US20240180968A1 (en) 2022-10-25 2024-06-06 Takeda Pharmaceutical Company Limited Adgre2 chimeric receptor nk cell compositions and methods of use

Also Published As

Publication number Publication date
US12540178B2 (en) 2026-02-03
ECSP23088752A (es) 2024-01-31
KR20240004287A (ko) 2024-01-11
WO2022232035A1 (en) 2022-11-03
IL307940A (en) 2023-12-01
CA3214355A1 (en) 2022-11-03
BR112023020371A2 (pt) 2024-02-06
AU2022266583A1 (en) 2023-10-19
AU2022266583A9 (en) 2023-10-26
CN117580860A (zh) 2024-02-20
EP4330283A1 (en) 2024-03-06
TW202305003A (zh) 2023-02-01
US20230018888A1 (en) 2023-01-19
JP2024518776A (ja) 2024-05-02
CO2023013195A2 (es) 2023-10-19
MX2023011712A (es) 2023-10-12
PE20242205A1 (es) 2024-11-19
CL2023003174A1 (es) 2024-05-24

Similar Documents

Publication Publication Date Title
AR125450A1 (es) Anticuerpos anti-adgre2 y usos de los mismos
CO2023014316A2 (es) Anticuerpos anti-clec12a y usos de los mismos
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
MX2020012587A (es) Anticuerpos anti-cd3 y usos de estos.
MX2019014465A (es) Anticuerpos especificos para flt3 y sus usos.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
UY37591A (es) Conjugados de fármaco anticuerpo
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2023006817A (es) Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
MX2020004220A (es) Anticuerpos anti-glico-muc1 y sus usos.
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
MX2021003119A (es) Anticuerpos anti-klrg1.
DOP2025000164A (es) Anticuerpos anti-unc5c
CO2024004055A2 (es) Polipéptidos
CO2022015030A2 (es) Anticuerpos anti-cd19 y sus usos
AR132465A1 (es) Anticuerpos lilrb1 y lilrb2 y métodos de uso de estos
CO2024015993A2 (es) Anticuerpos anti-tnfr2 y métodos de uso de estos